On June 7, Quick-Med Technologies will be presenting their new technology, NIMBUS, to a Congressional caucus on hospital infection prevention in the 21st century as a possible solution to preventing hospital acquired infections.
About NIMBUS:
The NIMBUS technology employs a powerful microbicidal agent that can be permanently bonded to materials such as cotton, rayon or polyurethane to create advanced wound dressings, fabrics or other medical products. The Company has recently announced the finding that NIMBUS is highly effective against key strains of bacteria that have become resistant to antibiotics commonly used to treat infections, including MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococcus) — two of the most important antibiotic-resistant organisms that cause hospital and nursing home infections.
HA MRSA, MRSA, Nimbus, Research and Development, Washington D.C.
1 response so far ↓
Bruce Smeaton // May 9, 2011 at 7:06 pm
Given your interest in MRSA I would invite you to go to the American Journal Of Infection Control (online if you don’t currently subscribe) and look at the “Articles In Press” in the current (May 2011) edition…and you will see the first one listed is a peer reviewed study entitled: Effectiveness of a Novel Ozone-Based System for the Rapid High-Level Disinfection of Healthcare Spaces and Surfaces”.
The journal article itself refers to an emerging infection control technology known as AsepticSure.
While the testing and clinical studies published in the article relate to “confined space” scenarios, the developer of AsepticSure is at an advanced stage in designing applications to deal with CAMRSA “hotspots” as well, such as: school locker rooms, gymnasiums, hotels, cruise ships etc.
Dr Michael Shannon (former Canadian Deputy Surgeon General) and Dr Dick Zoutman are just two of the string of eminent professionals working on this technology.
On the science side, you’ll be very intrigued to note that for the first time ever, 100% microbial kill rates measured as minimal reductions rates ranging from 6 – 7.9 log are being consistently achieved against spores including: MRSA, VRE, E.coli, P. aeruginosa, C.difficile and B.subtilis.
100% kill rates at these logs are unprecedented and open up the very real possibility of attacking CAMRSA as well.
If this is of interest to you, you could also do some good due diligence on the science behind the Asepticsure development by checking out the website of Medizone International.
Dr Zoutman is presenting AsepticSure to the World Health Organization-sponsored “First International Conference On Prevention & Infection Control” in Geneva at the end of June. So clearly, this is a development in the fight against superbugs and HAI’s that warrants more than just a cursory glance.
Hope you find this of interest.
Leave a Comment